TY - JOUR
T1 - The chromosome 21 kinase DYRK1A
T2 - emerging roles in cancer biology and potential as a therapeutic target
AU - Rammohan, Malini
AU - Harris, Ethan
AU - Bhansali, Rahul S.
AU - Zhao, Emily
AU - Li, Loretta S.
AU - Crispino, John D.
N1 - Funding Information:
This review was supported in part by the NIH (R35 CA253096). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Additional support was provided St. Jude/ALSAC. EH is supported by the American Society of Hematology’s Medical Student Physician-Scientist Award.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a serine/threonine kinase that belongs to the DYRK family of proteins, a subgroup of the evolutionarily conserved CMGC protein kinase superfamily. Due to its localization on chromosome 21, the biological significance of DYRK1A was initially characterized in the pathogenesis of Down syndrome (DS) and related neurodegenerative diseases. However, increasing evidence has demonstrated a prominent role in cancer through its ability to regulate biologic processes including cell cycle progression, DNA damage repair, transcription, ubiquitination, tyrosine kinase activity, and cancer stem cell maintenance. DYRK1A has been identified as both an oncogene and tumor suppressor in different models, underscoring the importance of cellular context in its function. Here, we review mechanistic contributions of DYRK1A to cancer biology and its role as a potential therapeutic target.
AB - Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a serine/threonine kinase that belongs to the DYRK family of proteins, a subgroup of the evolutionarily conserved CMGC protein kinase superfamily. Due to its localization on chromosome 21, the biological significance of DYRK1A was initially characterized in the pathogenesis of Down syndrome (DS) and related neurodegenerative diseases. However, increasing evidence has demonstrated a prominent role in cancer through its ability to regulate biologic processes including cell cycle progression, DNA damage repair, transcription, ubiquitination, tyrosine kinase activity, and cancer stem cell maintenance. DYRK1A has been identified as both an oncogene and tumor suppressor in different models, underscoring the importance of cellular context in its function. Here, we review mechanistic contributions of DYRK1A to cancer biology and its role as a potential therapeutic target.
UR - http://www.scopus.com/inward/record.url?scp=85125286450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125286450&partnerID=8YFLogxK
U2 - 10.1038/s41388-022-02245-6
DO - 10.1038/s41388-022-02245-6
M3 - Review article
C2 - 35220406
AN - SCOPUS:85125286450
SN - 0950-9232
VL - 41
SP - 2003
EP - 2011
JO - Oncogene
JF - Oncogene
IS - 14
ER -
